Impella Sales Drive Abiomed F2016 Q2 Revenues Up 47%
This article was originally published in Clinica
Executive Summary
Abiomed’s Protected PCI initiative, an effort to make the company’s Impella line of percutaneous heart pumps part of the standard of care for intervention in high risk patients, is off to a good start with 70% procedure growth in the US during the second fiscal quarter of 2016.